Pinnacle Wealth Management Advisory Group 13F: Adds $2.4M to LLY Stake

Pinnacle Wealth Management boosted its stake in Eli Lilly and Company LLY by 2,087 shares during the quarter, according to a Form 13F filing with the Securities and Exchange Commission on October 23, 2026.

LLY Eli Lilly and Company

$1,273.46 ▲ +18.44% year to date

1M 3M YTD

Daily close · Oct 23, 2026

What Changed in Pinnacle Wealth Management's Eli Lilly and Company Position

The firm grew its investment by 45.0%, bringing its total holding to 6,721 shares. The added shares brought the total value of the position to $7,776,747 based on the filing date valuation. The prior stake stood at 4,634 shares.

Other Institutional Activity in Eli Lilly and Company

Other institutional investors also adjusted their positions in the pharmaceutical giant during the filing window. Ascent Wealth Partners held 9,135 shares worth about $10.6 million. Evergreen Capital Management grew its holdings by 1,878 shares, ending with 14,030 shares valued at approximately $16.2 million. HB Wealth Management lifted its stake by 7,180 shares to 71,632 shares worth about $82.9 million. Symphony Financial added 1,205 shares for a total of 7,802 shares valued at roughly $9.2 million. Meanwhile, Wilmington Savings Fund Society trimmed its position by 2,600 shares, ending with 25,292 shares worth about $29.3 million.

Eli Lilly and Company Stock Up 0.2%

The drug maker's shares closed at $1,273.46 on October 23, 2026. The stock recently traded around $1273.57 on October 24, 2026, putting it about equal to its event-day close. The share price sits comfortably above its 50-day moving average of $1,185.32 and its 200-day moving average of $1,084.11. Over the past year, the stock has traded between a low of $806.02 and a high of $1,321.21.

Recent Earnings

Eli Lilly and Company reported trailing twelve month revenue of $79.67 billion alongside earnings of $29.79 per share. The company generated a net profit margin of 33.5% and a return on equity of 102.3%. Revenue grew 47.7% compared to the same period a year earlier. The next earnings report is scheduled for October 29, 2026.

Dividend

The company pays an annual dividend rate of $6.92 per share, which translates to a dividend yield of 0.53%. Management allocates 21.7% of earnings toward dividend payments through its payout ratio.

Insider Buying and Selling at Eli Lilly and Company

Company insiders completed several transactions prior to the filing. General Counsel Anat Hakim sold 5,000 shares on August 7, 2026, at an average price of $1,190.00 for a total value of $5,950,000. Officer Donald A Zakrowski sold 2,000 shares on August 10, 2026, at an average price of $1,185.01, totaling $2,370,020. Officer Patrik Jonsson sold 6,500 shares on August 17, 2026, at an average price of $1,175.10, yielding $7,638,150. None of these transactions were executed under a Rule 10b5-1 trading plan.

Analysts Set New Price Targets

Wall Street firms updated their views on the stock ahead of the filing. JP Morgan maintained an Overweight rating on September 28, 2026, raising its target to $1,500.00 from $1,400.00. Morgan Stanley kept an Overweight rating on October 7, 2026, lifting its target to $1,430.00 from $1,419.00. Cantor Fitzgerald maintained an Overweight rating on October 8, 2026, raising its target from $1,410.00 to $1,440.00. RBC Capital reiterated an Outperform rating on October 12, 2026, keeping its target at $1,500.00. Leerink Partners maintained an Outperform rating on October 21, 2026, pushing its target from $1,309.00 to $1,316.00. Overall, the stock carries a consensus buy rating from 30 analysts, with a mean price target of $1,331.55.

About Eli Lilly and Company

Eli Lilly and Company operates as a major healthcare enterprise headquartered in Indianapolis, Indiana. The firm discovers, develops, manufactures, and distributes human pharmaceutical products across domestic and international markets. Its therapies target metabolic disorders, oncology, immunology, and neuroscience conditions. Institutional interest remains strong as the company prepares for its upcoming quarterly financial update.

Bottom Line

Pinnacle Wealth Management expanded its investment as shares traded near the upper end of their 52-week range. Investors will look toward the upcoming earnings release on October 29, 2026, for further insight into financial performance and revenue trends.